DE60042821D1 - 6-alkenyl, 6-alkynyl und 6-epoxy- epothilon-derivate. verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen zusammensetzungen - Google Patents
6-alkenyl, 6-alkynyl und 6-epoxy- epothilon-derivate. verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen zusammensetzungenInfo
- Publication number
- DE60042821D1 DE60042821D1 DE60042821T DE60042821T DE60042821D1 DE 60042821 D1 DE60042821 D1 DE 60042821D1 DE 60042821 T DE60042821 T DE 60042821T DE 60042821 T DE60042821 T DE 60042821T DE 60042821 D1 DE60042821 D1 DE 60042821D1
- Authority
- DE
- Germany
- Prior art keywords
- alkynyl
- alkenyl
- epoxy
- production
- pharmaceutical compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19921086A DE19921086A1 (de) | 1999-04-30 | 1999-04-30 | 6-Alkenyl- und 6-Alkinyl-Epothilon Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
| DE19954228A DE19954228A1 (de) | 1999-11-04 | 1999-11-04 | 6-Alkenyl-und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
| DE10015836A DE10015836A1 (de) | 2000-03-27 | 2000-03-27 | 6-Alkenyl- und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
| PCT/IB2000/000657 WO2000066589A1 (en) | 1999-04-30 | 2000-05-01 | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60042821D1 true DE60042821D1 (de) | 2009-10-08 |
Family
ID=27213767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60042821T Expired - Lifetime DE60042821D1 (de) | 1999-04-30 | 2000-05-01 | 6-alkenyl, 6-alkynyl und 6-epoxy- epothilon-derivate. verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen zusammensetzungen |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1173441B1 (de) |
| JP (2) | JP4024003B2 (de) |
| KR (1) | KR100721488B1 (de) |
| CN (1) | CN100368415C (de) |
| AR (1) | AR023792A1 (de) |
| AT (1) | ATE440847T1 (de) |
| BG (1) | BG65601B1 (de) |
| BR (1) | BR0010190A (de) |
| CA (2) | CA2651653C (de) |
| CY (1) | CY1109768T1 (de) |
| CZ (1) | CZ299653B6 (de) |
| DE (1) | DE60042821D1 (de) |
| DK (1) | DK1173441T3 (de) |
| EA (1) | EA011502B1 (de) |
| EE (1) | EE05292B1 (de) |
| ES (1) | ES2331506T3 (de) |
| HK (1) | HK1046681B (de) |
| HR (1) | HRP20010892A2 (de) |
| HU (1) | HUP0201010A3 (de) |
| IL (1) | IL145938A0 (de) |
| ME (1) | MEP13908A (de) |
| MX (1) | MXPA01011039A (de) |
| NO (1) | NO328149B1 (de) |
| NZ (1) | NZ514989A (de) |
| PE (1) | PE20010116A1 (de) |
| PL (1) | PL210762B1 (de) |
| PT (1) | PT1173441E (de) |
| RS (1) | RS51023B (de) |
| SI (1) | SI1173441T1 (de) |
| SK (1) | SK286858B6 (de) |
| TW (2) | TWI294292B (de) |
| WO (1) | WO2000066589A1 (de) |
| ZA (1) | ZA200109859B (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997019086A1 (de) | 1995-11-17 | 1997-05-29 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilonderivate, herstellung und verwendung |
| ATE408612T1 (de) | 1996-11-18 | 2008-10-15 | Biotechnolog Forschung Gmbh | Epothilone e und f |
| CA2273083C (en) | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
| US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| US6518421B1 (en) * | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
| DE10020899A1 (de) * | 2000-04-20 | 2001-10-25 | Schering Ag | 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
| UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
| CN1489466A (zh) | 2001-01-25 | 2004-04-14 | ����˹�ж�-����˹˹������˾ | 包含埃博霉素类似物的非肠道制剂 |
| EP1938821B1 (de) | 2001-01-25 | 2016-03-30 | Bristol-Myers Squibb Company | Formulierung eines Epothilon-Analogs zur Krebsbehandlung |
| EP1368030A1 (de) | 2001-02-20 | 2003-12-10 | Bristol-Myers Squibb Company | Epothilon-derivative zur behandlung von refraktären tumoren |
| BR0207487A (pt) | 2001-02-20 | 2004-08-10 | Brystol Myers Squibb Company | Método de tratamento de tumores em mamìferos e uso de compostos de epotilona |
| ATE554756T1 (de) | 2001-03-14 | 2012-05-15 | Bristol Myers Squibb Co | Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen |
| MXPA03010909A (es) | 2001-06-01 | 2004-02-17 | Bristol Myers Squibb Co | Derivados de epotilona. |
| EP1340498A1 (de) * | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Verwendung von Epothilonen zur Behandlung von mit proliferativen Prozessen assoziierten Gehirnerkrankungen |
| ATE452896T1 (de) | 2002-03-12 | 2010-01-15 | Bristol Myers Squibb Co | C3-cyanoepothilonderivate |
| US7211593B2 (en) | 2002-03-12 | 2007-05-01 | Bristol-Myers Squibb Co. | C12-cyano epothilone derivatives |
| TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| US7008936B2 (en) | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| EP2280014B1 (de) | 2002-09-23 | 2013-10-23 | Bristol-Myers Squibb Company | Verfahren zur Herstellung, Isolierung und Aufreinigung von Epothilon B |
| DE10361794B3 (de) * | 2003-12-31 | 2005-10-06 | Schering Ag | Optisch aktive heteroaromatische ß-Hydroxy-Ester und Verfahren zu deren Herstellung sowie deren Verwendung als Zwischenprodukte bei der Epothilon-Totalsynthese |
| EP1559447A1 (de) | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Verwendung von Epothilonen zur Behandlung von neuronalen Konnektivitätsdefekten wie zum Beispiel Schizophrenie und Autismus |
| EP1640004A1 (de) * | 2004-09-24 | 2006-03-29 | Schering Aktiengesellschaft | Verwendung von Epothilonen zur Behandlung von Knochenmetastasen und Knochentumoren oder Knochenkrebs |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| EP1674098A1 (de) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit |
| CN100384419C (zh) * | 2005-12-02 | 2008-04-30 | 菏泽睿鹰制药集团有限公司 | 一种埃坡霉素缓释植入组合物及应用 |
| DE102007016046A1 (de) | 2007-03-30 | 2008-10-23 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung |
| EP2065054A1 (de) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Kombinationen mit einem Prostaglandin und Verwendungen davon |
| EP2070521A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Nanopartikel mit modifizierter Oberfläche |
| DE102007059752A1 (de) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
| EP2210584A1 (de) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stabile Polymerzusammensetzung mit einem Epothilon und einem amphiphilischen Blockpolymer |
| CA2799202C (en) | 2010-05-18 | 2016-07-05 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| AU2012356894B2 (en) | 2011-12-23 | 2018-01-18 | Innate Pharma | Enzymatic conjugation of polypeptides |
| WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
| EP2916872B1 (de) | 2012-11-09 | 2019-02-27 | Innate Pharma | Kennungen für tgase-vermittelte konjugation |
| WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
| US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
| JP6744212B2 (ja) | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | ポリペプチドの酵素的結合 |
| WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54115320A (en) * | 1978-02-28 | 1979-09-07 | Soda Aromatic | Novel unsaturated keto acid and its manufacture |
| JP2653663B2 (ja) * | 1988-02-15 | 1997-09-17 | 財団法人微生物化学研究会 | １．３―ジヒドロキシ―８―デセン―５―オンを含む免疫賦活剤及び制癌剤 |
| EP0469480A3 (en) * | 1990-08-01 | 1993-03-10 | Hoechst Aktiengesellschaft | Process for stereoselective preparation of 5-substituted delta-lactones and their use |
| WO1998038192A1 (de) * | 1997-02-25 | 1998-09-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Seitenkettenmodifizierte epothilone |
| DE59814067D1 (de) * | 1997-08-09 | 2007-09-06 | Bayer Schering Pharma Ag | Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
-
2000
- 2000-04-28 PE PE2000000403A patent/PE20010116A1/es not_active Application Discontinuation
- 2000-04-28 AR ARP000102024A patent/AR023792A1/es active IP Right Grant
- 2000-05-01 CA CA2651653A patent/CA2651653C/en not_active Expired - Fee Related
- 2000-05-01 JP JP2000615619A patent/JP4024003B2/ja not_active Expired - Fee Related
- 2000-05-01 CZ CZ20013885A patent/CZ299653B6/cs not_active IP Right Cessation
- 2000-05-01 SK SK1551-2001A patent/SK286858B6/sk not_active IP Right Cessation
- 2000-05-01 CA CA2371226A patent/CA2371226C/en not_active Expired - Fee Related
- 2000-05-01 DE DE60042821T patent/DE60042821D1/de not_active Expired - Lifetime
- 2000-05-01 NZ NZ514989A patent/NZ514989A/xx not_active IP Right Cessation
- 2000-05-01 CN CNB008069786A patent/CN100368415C/zh not_active Expired - Fee Related
- 2000-05-01 EE EEP200100568A patent/EE05292B1/xx not_active IP Right Cessation
- 2000-05-01 ES ES00922826T patent/ES2331506T3/es not_active Expired - Lifetime
- 2000-05-01 EA EA200101025A patent/EA011502B1/ru not_active IP Right Cessation
- 2000-05-01 AT AT00922826T patent/ATE440847T1/de active
- 2000-05-01 MX MXPA01011039A patent/MXPA01011039A/es active IP Right Grant
- 2000-05-01 BR BR0010190-7A patent/BR0010190A/pt not_active IP Right Cessation
- 2000-05-01 EP EP00922826A patent/EP1173441B1/de not_active Expired - Lifetime
- 2000-05-01 ME MEP-139/08A patent/MEP13908A/xx unknown
- 2000-05-01 WO PCT/IB2000/000657 patent/WO2000066589A1/en active IP Right Grant
- 2000-05-01 IL IL14593800A patent/IL145938A0/xx unknown
- 2000-05-01 PT PT00922826T patent/PT1173441E/pt unknown
- 2000-05-01 RS YUP-776/01A patent/RS51023B/sr unknown
- 2000-05-01 KR KR1020017013840A patent/KR100721488B1/ko not_active IP Right Cessation
- 2000-05-01 DK DK00922826T patent/DK1173441T3/da active
- 2000-05-01 HU HU0201010A patent/HUP0201010A3/hu unknown
- 2000-05-01 PL PL351491A patent/PL210762B1/pl not_active IP Right Cessation
- 2000-05-01 SI SI200031044T patent/SI1173441T1/sl unknown
- 2000-05-18 TW TW095145399A patent/TWI294292B/zh not_active IP Right Cessation
- 2000-05-18 TW TW89108133A patent/TWI280962B/zh not_active IP Right Cessation
-
2001
- 2001-10-26 BG BG106053A patent/BG65601B1/bg unknown
- 2001-10-29 NO NO20015278A patent/NO328149B1/no not_active IP Right Cessation
- 2001-11-29 ZA ZA200109859A patent/ZA200109859B/xx unknown
- 2001-11-30 HR HR20010892A patent/HRP20010892A2/xx not_active Application Discontinuation
-
2002
- 2002-11-13 HK HK02108204.3A patent/HK1046681B/zh not_active IP Right Cessation
-
2007
- 2007-04-11 JP JP2007104224A patent/JP4886578B2/ja not_active Expired - Fee Related
-
2009
- 2009-11-25 CY CY20091101237T patent/CY1109768T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60042821D1 (de) | 6-alkenyl, 6-alkynyl und 6-epoxy- epothilon-derivate. verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen zusammensetzungen | |
| ATE302754T1 (de) | Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| DE60033028D1 (de) | 5-pyridyl-1,3-azol-derivate, verfahren zu ihrer herstellung und ihre verwendung | |
| DE50102147D1 (de) | Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| ATE370946T1 (de) | 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung | |
| ATE252578T1 (de) | 1,3-oxazolin- und 1,3-thiazolin-derivate, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel | |
| ATE222250T1 (de) | Phenoxypropanolamin-derivate, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen zusammensetzungen | |
| ATE252562T1 (de) | Pyrazolcarbonsäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| DE10393704D2 (de) | Nancomposite, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| ATE272634T1 (de) | Benzothiophenderivate, verhahren zu ihrer herstellung und ihre verwendung | |
| ATE327981T1 (de) | Arylisoxazolin-derivative, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel | |
| DE60103395D1 (de) | 1,4-diazabicyclo[3.2.2]nonanbenzoxazol-, benzothiazol- und benzoimidazolderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
| DE50011818D1 (de) | Hochkratzfeste mehrschichtlackierung, verfahren zu ihrer herstellung und ihre verwendung | |
| ATE323092T1 (de) | Pyridopyrimidinon-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| ATE337317T1 (de) | Imidazopyrin-derivate, verfahren zu ihrer herstellung and sie enthaltende pharmazeutische zusamensetzungen | |
| ATE304534T1 (de) | Aminocarbonyl-substituierte benzimidazolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| DE50105965D1 (de) | Perfluoralkylhaltige komplexe mit zuckerresten, verfahren zu deren herstellung und ihre verwendung | |
| ATE301645T1 (de) | Polycyclische thiazolidin-2-yliden amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| DE60013418D1 (de) | Morpholinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen | |
| ATE250578T1 (de) | Indenoindolon-derivate, verfahren zu ihrer herstellung und die enthaltenden pharmazeutischen zusammensetzungen | |
| ATE313556T1 (de) | Memno-peptide, verfahren zu ihrer herstellung und ihre verwendung | |
| ATE248843T1 (de) | Benzothiadiazinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| ATE288442T1 (de) | Cyclipostine, verfahren zu ihrer herstellung und verwendung derselben | |
| DE50107787D1 (de) | Acesulfam-Metall-Komplexe, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE59908123D1 (de) | 2,5-substituierte benzolsulfonylharnstoffe und -thioharnstoffe, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmzeutische präparate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |